Document Detail


N,N'-diacetylchitobiose, an inhibitor of lysozyme, reverses myocardial depression and lessens norepinephrine requirements in Escherichia coli sepsis in dogs.
MedLine Citation:
PMID:  17885642     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular dysfunction in septic shock (SS) is ascribed to the release of inflammatory mediators. Norepinephrine (NE) is often administered to treat low MAP in SS. We recently found that lysozyme c (Lzm-S) released from leukocytes was a mediator of myocardial depression in an Escherichia coil model of SS in dogs. This effect can be blocked in an in vitro preparation by chitobiose, a competitive inhibitor of Lzm-S. In the present study, we examined whether chitobiose treatment can reverse myocardial depression and obviate NE requirements in two respective canine E. coli preparations. In a 6-h study, we administered chitobiose after 3.5 h of E. coli bacteremia and compared stroke work (SW) and MAP at 6 h with a sepsis control group. In a 12-h study, we determined whether chitobiose treatment can reduce the need for NE requirements during 12 h of bacteremia. In the latter study, either chitobiose or NE was given when MAP decreased approximately 20% from the presepsis value in respective groups. In anesthetized, mechanically ventilated dogs, we monitored hemodynamic parameters during continuous E. coli infusion. In the 6-h study, chitobiose improved SW and MAP at the 6-h period as compared with the nontreated sepsis group. In the 12-h study, SW and MAP increased after chitobiose without the necessity of NE administration. These results suggest that inhibitors of Lzm-S such as chitobiose may improve myocardial depression and reduce the need for NE requirements in SS.
Authors:
Steven N Mink; Krika Kasian; Hans Jacobs; Zhao-Qin Cheng; R Bruce Light
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Shock (Augusta, Ga.)     Volume:  29     ISSN:  1073-2322     ISO Abbreviation:  Shock     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-08-13     Completed Date:  2008-09-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421564     Medline TA:  Shock     Country:  United States    
Other Details:
Languages:  eng     Pagination:  681-7     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. minksn@cc.umanitoba.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bacteremia / drug therapy,  enzymology,  physiopathology
Cardiomyopathies / drug therapy*,  enzymology,  physiopathology
Disaccharides / pharmacology*
Dogs
Enzyme Inhibitors / pharmacology*
Escherichia coli*
Escherichia coli Infections / drug therapy*,  enzymology,  physiopathology
Humans
Inflammation Mediators / metabolism
Male
Muramidase / antagonists & inhibitors*
Norepinephrine / pharmacology*
Shock, Septic / drug therapy*,  enzymology,  physiopathology
Stroke Volume / drug effects
Time Factors
Vasoconstrictor Agents / pharmacology*
Chemical
Reg. No./Substance:
0/Disaccharides; 0/Enzyme Inhibitors; 0/Inflammation Mediators; 0/Vasoconstrictor Agents; 2706-64-1/N,N-diacetylchitobiose; 51-41-2/Norepinephrine; EC 3.2.1.17/Muramidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The impact of CMSA's case management adherence guidelines and guidelines training on case manager-re...
Next Document:  Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to...